188 related articles for article (PubMed ID: 34487230)
1. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Hui M; Chen M
Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
[No Abstract] [Full Text] [Related]
2. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Brugger W; Ghielmini M
Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
[TBL] [Abstract][Full Text] [Related]
3. [Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Du KX; Shen HR; Wang L; Liang JH; Wu JZ; Li Y; Xia Y; Yin H; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):333-336. PubMed ID: 37357004
[No Abstract] [Full Text] [Related]
4. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
7. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
8. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
[TBL] [Abstract][Full Text] [Related]
10. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Plosker GL; Carter NJ
Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
[TBL] [Abstract][Full Text] [Related]
12. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
[No Abstract] [Full Text] [Related]
13. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine in lymphomas: more to combine?
Bertoni F; Zucca E
Leuk Lymphoma; 2007 Jul; 48(7):1264-6. PubMed ID: 17613752
[No Abstract] [Full Text] [Related]
16. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
19. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
[TBL] [Abstract][Full Text] [Related]
20. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
